Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) passed the on-site inspection by the US FDA.
Northeastern Biomedical (688076.SH) announced that the company will be closed from September 12, 2024 to September 20, 2024.
Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) announced that from September 12, 2024 to September 20, 2024, the company underwent a cGMP (Current Good Manufacturing Practice) inspection by the United States Food and Drug Administration (FDA). Recently, the company received the Establishment Inspection Report (EIR) issued by the FDA, which indicated that the company's production base in Jiangsu Lianyungang Port Economic and Technological Development Zone in Jiangsu Province at 28 Linpu Road successfully passed the cGMP on-site inspection.
Related Articles

Broad strategy: A-shares may usher in a new round of upward cycle in the future.

Zhejiang Tenchen Controls' subsidiary has become a supplier of passenger car seats for a domestic automotive company in China.

Yiwu Huading Nylon (601113.SH) shareholders in Yiwu Economic Development Zone plan to transfer up to 6% of their shares through public solicitation.
Broad strategy: A-shares may usher in a new round of upward cycle in the future.

Zhejiang Tenchen Controls' subsidiary has become a supplier of passenger car seats for a domestic automotive company in China.

Yiwu Huading Nylon (601113.SH) shareholders in Yiwu Economic Development Zone plan to transfer up to 6% of their shares through public solicitation.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


